ClinicalTrials.gg
Not yet recruitingNCT05453565FRESHLYUpdated Nov 9, 2026

Restricted or Liberal Fluid for Haemodynamic Resuscitation in Sepsis

An observational study in Septic Shock and Fluid Resuscitation, sponsored by Australian and New Zealand Intensive Care Research Centre. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Australian and New Zealand Intensive Care Research Centre · Observational

How we know

Updated Nov 9, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
7,838
Ages
18 Years and older
Sex
All
01

Study summary

A prospective, individual patient data meta-analysis (IPDMA) of four multicentre, open-label, randomised clinical trials of initial haemodynamic resuscitation in patients with septic shock.

Read the detailed description

This study is a prospective, individual patient data meta-analysis (IPDMA) of four multicentre, open-label, randomised clinical trials of initial haemodynamic resuscitation in patients with septic shock.

The investigators will include four multicentre, open-label, randomised, clinical trials:

  • Australasian Resuscitation in Sepsis Evaluation Fluids of Vasopressors in Emergency Department Sepsis (ARISE FLUIDS) trial conducted in Australia and New Zealand. ClinicalTrials.gov identifier NCT04569942
  • Conservative versus Liberal Approach to fluid therapy of Septic Shock in intensive Care (CLASSIC) trial conducted in seven European countries. ClinicalTrials.gov identifier NCT03668236
  • Crystalloid Liberal or Vasopressors Early (CLOVERS) trial conducted in the United States. ClinicalTrials.gov identifier NCT03434028
  • Early Vasopressors in Sepsis (EVIS) trial conducted in the United Kingdom. ClinicalTrials.gov identifier NCT05179499

All four trials have all received relevant approval from a research ethics committee with a locally appropriate method of obtaining consent. These trials are prospectively chosen prior to the results of any individual trial being known because they are investigating the same broad question in patients with acute septic shock across several countries. The investigators of these trials collaborated to harmonise data and outcomes as far as possible across all trials to facilitate an IPDMA.

The aims to provide high level evidence to address the question of whether a fluid sparing/early vasopressor approach or a liberal fluid/later vasopressor approach to initial haemodynamic resuscitation in septic shock results in improved outcomes, including mortality.

02

Conditions studied

  • Septic Shock
  • Fluid Resuscitation

Browse trials for

03

In context

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

This study's planned enrollment of 7,838 is above the median of 108 across 408 observational studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

Australian and New Zealand Intensive Care Research Centre is the lead sponsor of 49 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All trials include adult patients requiring resuscitation for hypotension or hypoperfusion due to suspected sepsis as defined in the original studies. Participants may be enrolled in the emergency department, acute care ward or intensive care unit.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants of the ARISE FLUIDS, CLASSIC, CLOVERS \& EVIS trials who had:

  • Suspected or proven infection
  • Systolic blood pressure (SBP) \<100 mm Hg OR mean arterial pressure (MAP) \<65 mm Hg
  • Lactate ≥ 2.0 mmol/L
  • Requirement for vasopressors to meet perfusion targets

Exclusion criteria

Exclusion criteria:

Participants not in the ARISE FLUIDS, CLASSIC, CLOVERS \& EVIS trials

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
7,838 participants (estimated)
Patient registry
No

Groups and cohorts

  • Vasopressors

    A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets

    Other: Vasopressors

  • Fluids

    A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.

    Other: Fluids

Interventions

  • OtherVasopressors

    A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets

  • OtherFluids

    A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.

06

What researchers measure

Primary outcomes

  1. All-cause mortality at 90 days post randomisation

    Death from any cause at 90 days after randomisation

    Time frame: 90 days

Secondary outcomes

  1. Time from randomisation to death

    Time from randomisation to death

    Time frame: Up to day 90

  2. Incidence of mechanical ventilation

    Commencement of mechanical ventilation from randomisation until day 90 post-randomisation

    Time frame: from randomisation until day 90 post-randomisation

  3. Incidence of acute renal replacement therapy

    Commencement of renal replacement therapy from randomisation until day 90 post-randomisation

    Time frame: from randomisation until day 90 post-randomisation

  4. Days alive free of organ support at 28 days post randomisation

    days the patient is alive and receiving nil organ support from from randomisation until day 28 post-randomisation

    Time frame: from randomisation until day 28 post-randomisation

  5. Duration of hospital stay

    Length of time in hospital from randomisation until death or hospital discharge or day 90 post-randomisation

    Time frame: From randomisation until day 90 post-randomisation

  6. Incidence of serious adverse events

    Number of adverse events from randomisation until day 90 post-randomisation

    Time frame: from randomisation until day 90 post-randomisation

  7. Duration of intensive care unit (ICU) stay

    Length of time in ICU from randomisation until death or hospital discharge or day 90 post-randomisation

    Time frame: From randomisation until day 90 post-randomisation

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2027; primary completion for Nov 2028, 12 months later.

Of 189 non-industry observational studies under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 12 months is below that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Nov 2025 → Nov 2027, primary completion Nov 2026 → Nov 2028 and completion Nov 2026 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2022
First posted
Jul 12, 2022
StartEst.
Nov 2027was Nov 2025
Primary completionEst.
Nov 2028was Nov 2026
CompletionEst.
Nov 2028was Nov 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 2025→Nov 2027
Nov 9, 2026
Primary completion
Nov 2026→Nov 2028
Nov 9, 2026
Study completion
Nov 2026→Nov 2028
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Start date Nov 2025→Nov 2027
    Primary completion Nov 2026→Nov 2028
    Study completion Nov 2026→Nov 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05453565
Lead sponsor
Australian and New Zealand Intensive Care Research Centre
Responsible party
Sponsor
First posted
Jul 12, 2022
Start date
Nov 2027 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion